US EditionAstraZeneca may quit London stock market
GREATER LONDON, ENGLAND, JUL 1 – AstraZeneca CEO cites UK regulatory hurdles and tax concerns amid plans to move listing to US, where over 40% of the company's $54 billion revenue is generated.
- AstraZeneca's chief executive Sir Pascal Soriot is reportedly considering shifting the company's stock market listing from London to the US as of July 2025.
- This consideration follows years of frustration with the UK's tax regime, NHS drug rebate scheme, and regulatory barriers hindering new medicine approvals.
- AstraZeneca has already invested more heavily in the US and China, including a $2.5 billion investment and plans for a new R&D center in Beijing.
- Soriot stated, “Companies will follow where they feel welcome,” highlighting that investment flows to favorable markets, while AstraZeneca's shares fell 17% in the past year before a 2.8% rise.
- Such a decision would significantly damage the London Stock Exchange and pose a serious threat to the UK's life sciences industry, heightening worries about the nation's ability to remain competitive.
Insights by Ground AI
Does this summary seem wrong?
28 Articles
28 Articles
AstraZeneca exit is a frightening prospect for the City and the government
Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to allow the FTSE 100's biggest company to leave London in favour of New York.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources28
Leaning Left3Leaning Right5Center7Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 20%
C 47%
R 33%
Factuality
To view factuality data please Upgrade to Premium
